08 June 2021
Made for each other - for better product stability & mating outcomes
24 May 2021
If your dairy farmers need a helping hand to improve their six week in-calf (6WIC) rates this spring, now’s the time to be planning ahead for timely intervention with non-cyclers.
The benefits of a well-executed non-cycler programme are thoroughly documented – more milk in the vat, more AB calves, a shorter calving spread; more time for those cows to get back in-calf next season, and less likelihood of farmers having to face culling good cows simply because they don’t show heat in time.
But as New Zealand-owned veterinary medicine company AgriHealth points out, not all intervention programmes are equal, and it pays to weigh the options carefully.
“Vets and farmers both want the best possible outcome from any non-cycler programme,” says AgriHealth Technical manager Dr. Laura Young
“It’s an investment not only in improved financial performance, but also future sustainability for New Zealand dairy herds, and like any investment, it deserves careful thought and implementation.”
NZ research has shown treating non-cyclers with AgriHealth’s Cyclase (3 mL dose) as part of a planned reproductive programme improves in-calf rates by 3 per cent.
But the biggest benefit comes from using Cyclase with AgriHealth’s Novormon eCG, because this improves early in-calf rates by 7 per cent, she says.
“eCG supports the developing follicle and its inclusion in a reproductive program results in a more effective corpora lutea (CL) following ovulation. More circulating progesterone in the oestrus cycle after ovulation can improve conception rates, reduces embryonic loss and reduces the incidence of ‘phantom’ cows.”
There’s a significant practical advantage associated with this particular combination, because it remains stable in solution for 21 days refrigerated, and 14 days at room temperature, compared to same day use if alternative Cyclase products used for reconstitution of Novormon eCG.
That in turn reduces product wastage as vets can use reconstituted product for 21 days, and also cuts down on the amount of packaging to dispose of.
In terms of product stewardship, Cyclase PG is the only such prostaglandin product in the NZ market approved by the ACVM for use in combination with Novormon eCG for anoestrus treatment, and this is another key point for vets to consider.
Hence AgriHealth’s emphasis on the two being ‘made for each other’ this season, to remind vets of the label claim as well as prescribing the best program for their clients.
With the national 6WIC rate remaining virtually flat for the past 10 years, Dr. Young says there’s good reason for dairy vets and their farmers to take a big picture approach to shifting the dial with non-cyclers this season.
“Cow and herd management obviously have a huge role to play here; intervention is just part of the process. But it is a proven strategy to improve early in-calf rates, with compelling returns.”
Using the best non-cycler programs (such as Cyclase plus Novormon eCG) results in higher in-calf rates and treated cows averaging 19 more days in milk, compared to untreated non-cyclers, NZ data shows.
“This extra milk yield leaves a healthy profit even after deducting costs of treatment. And that doesn’t even factor in the broader systemic gains associated with achieving more AB calves, condensing the calving spread and so on.”
For more detail phone 0800 821 421 or contact your local AgriHealth sales manager.